ImmuCell (ICCC) Q4 2025 earnings summary

Executive summary

• Achieved total product sales of $27.6 million in 2025, up 4.3% year-over-year, with net operating profit of $1.6 million, a $3.3 million improvement from 2024, driven by expanded gross margins, higher volumes, and manufacturing efficiencies.

• Net loss for 2025 was $1.0 million, an improvement of $1.1 million compared to 2024, impacted by non-recurring items including asset and inventory write-downs and CEO transition expenses, partially offset by insurance proceeds.

• Hired a new management team, increased manufacturing capacity, and resolved a multi-year backorder situation.

• Pivoted strategy to focus on maximizing value from the First Defense franchise, pausing investment in other product lines.

Financial highlights

• Product sales increased 4.3% to $27.6 million for 2025 compared to 2024.

• Gross margin improved to 41.4% for full year 2025 from 30% in 2024; Q4 2025 gross margin was 38%, up from 37% in Q4 2024, despite non-cash inventory write-downs.

• Operating expenses rose to $9.8 million in 2025, mainly due to higher G&A, partially offset by lower product development costs.

• EBITDA for 2025 was $2.2 million, up from $1.1 million in 2024.

• Ended 2025 with $3.8 million in cash and working capital of $13 million, up from $10.6 million at end of 2024.

Outlook and guidance

• Growth rates in early 2026 will be impacted by prior backorder catch-up, but operational momentum remains strong.

• Confident in meeting demand for 2026 and 2027 through yield improvements and planned capacity expansion to 5–6 million units annually.

• Management expects positive results from ongoing investments in commercial expansion and manufacturing yield improvements.

• Commercial focus shifting from managing allocations to proactive customer acquisition and top-line growth.